For Research Use Only. Not for Human Consumption.
Recorded market$75.33Recorded exact-size market estimate: 75.33 USD for one 10 mg container (7.532846 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$75.00Member price$39.4047.6% lessMembers save $35.93 on this item vs. recorded market
BPC-157 and TB-500 combination for repair research.
The 10 mg total label comprises 5 mg BPC-157 + 5 mg TB-500; the 20 mg total label comprises 10 mg + 10 mg. Totals include both components.
Exact-size price research
Supplier observation dates: Oct 11, 2026 UTC. This reference uses recorded prices for the same 10 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$3.94/mg47.6% less
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 04:30 UTC. Catalog label: 5 mg BPC-157 + 5 mg TB-500 = 10 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| PS Peptides Oct 11, 2026 UTC | One 10 mg container; 59.99 USD | $6.00/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Core Peptides Oct 11, 2026 UTC | One 10 mg container; 105.00 USD | $10.50/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Pure Lab Peptides Oct 11, 2026 UTC | One 10 mg container; 99.98 USD | $10.00/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| OGOmed Oct 11, 2026 UTC | One 10 mg container; 107.00 USD | $10.70/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Prime Lab Peptides Oct 11, 2026 UTC | One 10 mg container; 70.00 USD | $7.00/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| Healius Peptides Oct 11, 2026 UTC | One 10 mg container; 114.95 AUD | $8.02/mg | lyophilized powder; BackOrder (schema; selected display no stock text) Price observation; no COA authentication is implied by inclusion. |
| Nupex / Research Scientific Ltd Oct 11, 2026 UTC | One 10 mg container; 22.08 GBP | $2.92/mg | dry or lyophilized powder (publisher stated); InStock Price observation; no COA authentication is implied by inclusion. |
| Pure Peptides Australia Oct 11, 2026 UTC | One 10 mg container; 109.99 AUD | $7.68/mg | lyophilized powder; out of stock Price observation; no COA authentication is implied by inclusion. |
| BioLab Peptides UK Oct 11, 2026 UTC | One 10 mg container; 50.00 GBP | $6.61/mg | lyophilized powder; in stock Price observation; no COA authentication is implied by inclusion. |
| Cosmic Peptides Oct 11, 2026 UTC | One 10 mg container; 58.99 USD | $5.90/mg | lyophilized powder; in stock; web checkout temporarily disabled publisher notice Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “Wolverine Blend – 10 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/wolverine-blend-5-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/wolverine-blend-5-mg/
A combination vial of BPC-157 and TB-500 prepared for laboratory studies that examine complementary repair pathways together.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
Wolverine Stack is a marketing name for a peptide combination, commonly described as BPC-157 with a TB-500-related ingredient. Its composition must be established before any evidence can be evaluated.
They are different materials with different evidence, not interchangeable names for a recovery treatment. BPC-157 is a 15-amino-acid peptide. An analytical study of a TB-500 preparation identified the acetylated seven-residue fragment Ac-LKKTETQ. Neither that preparation nor a commercial product name should silently stand in for full-length thymosin beta-4.
The useful comparison is what a study actually tested. A paper about identifying a substance, a cell-migration experiment and a patient outcome answer different questions. The table below compares selected original studies; it is not an exhaustive review or a ranking of treatments.
| Study material | What the study measured | What it cannot settle |
|---|---|---|
| BPC-157 | A rat-tendon explant and fibroblast study examined outgrowth, survival under stress and cell migration. It did not find a direct proliferation effect in its reported MTT assay. | Which product heals a person’s injury faster, or whether a combination improves recovery. |
| Ac-LKKTETQ in a TB-500 preparation | A 2012 analytical study identified the fragment and described detection methods. | Clinical benefit, safety or the contents of every other product labeled TB-500. |
| TB-500 parent fragment and metabolites | A 2024 metabolism and cell-assay study reported significant wound-assay activity for Ac-LKKTE, a metabolite, rather than the parent form. | Human tendon healing or a benefit from adding BPC-157. |
No. These three studies are not a head-to-head clinical comparison. Their materials, models and outcomes differ. The broader BPC-157 profile discusses its limited human reports separately; the TB-500 profile explains the fragment-identity problem. Neither a longer bibliography nor a plausible mechanism supplies the missing comparison.
Try this fictional claim: “Study A found more BPC-157 cell migration, and Study B found activity for a TB-500 metabolite, so the blend must repair an injury twice as fast.” There is no measured “twice as fast” result in that reasoning. It changes the material from metabolite to parent, moves from laboratory outcomes to patient recovery, and adds a combination that those experiments did not test.
For a useful comparison note, record exact material → model or population → comparator → measured outcome → follow-up → single ingredient or combination. Leave an unanswered field visible. Do not replace it with the familiar “local versus systemic” shorthand or turn the record into a dosing schedule.
Comparison added October 23, 2026. Reading scope: the linked primary-study abstracts and bibliographic records, not full-text review. The findings do not authenticate catalog products or establish human-use suitability.
The name does not define a fixed sequence, ratio or formulation. TB-500 itself can refer to materially different thymosin beta-4-related products.
Separate co-packaged products, a premixed vial and an engineered delivery system. They are not one interchangeable intervention.
The source-page papers largely investigate separate ingredients or complex experimental delivery systems. They do not establish the clinical effect of the advertised combination. A plausible interaction or two favorable ingredient studies cannot demonstrate synergy without a study designed to test the combination.
| Study and design | Finding | What it does not establish |
|---|---|---|
| The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.
Rat-tendon explants and fibroblast experiments with BPC-157 Reading scope: PubMed bibliographic record and abstract |
BPC-157 affected explant outgrowth, cell survival under stress and migration-related measures. | The study did not test a BPC-157/TB-500 combination or human return to activity. |
| TB-500 fragment metabolism and fibroblast assays
Rat and in-vitro analytical research Reading scope: PubMed abstract |
One identified metabolite showed activity in a wound-healing assay. | This does not establish either the parent fragment’s clinical benefit or synergy with BPC-157. |
| Injectable Thymosin β4-Modified Hyaluronic Acid Hydrogel with Exosomes for Stem Cell Homing and Neuronic-Angiogenic-Osteogenic Coupled Cranial Repair.
Cell experiments and rat bone repair using a beta-4/exosome hydrogel Reading scope: PubMed bibliographic record and abstract |
An engineered scaffold showed favorable regenerative findings in its models. | The hydrogel, exosomes and delivery design are different from a simple commercially named stack. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
Synergy means more than two ingredients having interesting mechanisms. It needs appropriately compared ingredient-alone and combination groups with a defined outcome.
Healing endpoints are also different: cell migration, tissue appearance, pain and functional recovery cannot be substituted for one another.
A combination can introduce compatibility, stability and attribution problems. A response or adverse event cannot readily be assigned to one component when several are used together.
The selected ingredient and delivery-system studies do not establish a safety profile for a premixed combination. Lack of direct combination evidence should remain beside claims of accelerated recovery.
An exposure used for one ingredient cannot be converted into a combination schedule by simply adding a second one. Preserve the actual model, delivery system and ingredient amounts when reading a paper.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Request the exact identities and per-component quantities, not only the blend’s total mass. A single purity percentage may not characterize a multi-peptide mixture; the analytical method must be suitable for the components and any degradation products.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. The reviewed papers concern components or different engineered systems, rather than a defined commercial stack in a controlled patient trial.
No. Combining claims is not evidence that the combination works, is compatible or has an acceptable benefit-risk profile.
No. It must state the identity and quantity of each constituent and whether the beta-4-related component is full-length or a fragment.
This companion to the Wolverine Stack research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
An exposure used for one ingredient cannot be converted into a combination schedule by simply adding a second one. Preserve the actual model, delivery system and ingredient amounts when reading a paper.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.